Determination of IGF-I, IGF-II, IGFBP-2, and IGFBP-3 levels in serum and plasma: comparisons using the Bland-Altman method

被引:25
作者
Renehan, AG
Jones, J
O'Dwyer, ST
Shalet, SM
机构
[1] Christie Hosp NHS Trust, Dept Surg, Manchester M20 4BX, Lancs, England
[2] Kings Coll London, Sch Med & Dent, Diabet Lab, London, England
[3] Kings Coll London, Sch Med & Dent, Met Lab, London, England
[4] Christie Hosp NHS Trust, Dept Endocrinol, Manchester M20 4BX, Lancs, England
关键词
insulin-like growth factors; IGF binding proteins; Bland-Altman plots;
D O I
10.1016/S1096-6374(03)00112-6
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The measurement of circulating insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs) have significant implications in the risk assessment of various diseases (e.g. cancer) and growth abnormalities. It is often assumed that values measured in serum and plasma are interchangeable. This study challenges this assumption by comparing determinants using the Bland-Altman method. Blood was obtained from 47 healthy volunteers (age 21-72 years) in serum, heparin plasma and EDTA plasma, and IGF-I, IGF-II, IGFBP-2, and IGFBP-3 measured, and results compared. Mean values for IGF-I, IGF-II, IGFBP-2 and IGFBP-3 determined in all three media were generally comparable; correlations were generally strong and significant (P < 0.001). However, the Bland-Altman plots revealed significant lack of agreement for many analytes measured in EDTA plasma compared with serum and heparin plasma. Additionally, the ranges of the limits of agreement were consistently greater for EDTA plasma compared with the other two methods. These findings emphasize the need to standardize methods of collecting blood samples in future epidemiological studies and trials. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:341 / 346
页数:6
相关论文
共 21 条
[1]   Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix [J].
Arai, T ;
Busby, W ;
Clemmons, DR .
ENDOCRINOLOGY, 1996, 137 (11) :4571-4575
[2]   STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[3]   ELEVATED LEVELS OF INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-2 IN THE SERUM OF PROSTATE-CANCER PATIENTS [J].
COHEN, P ;
PEEHL, DM ;
STAMEY, TA ;
WILSON, KF ;
CLEMMONS, DR ;
ROSENFELD, RG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 76 (04) :1031-1035
[4]   Insulin-like growth factor I and its binding proteins in the cardiovascular system [J].
Delafontaine, P .
CARDIOVASCULAR RESEARCH, 1995, 30 (06) :825-834
[5]   The heparin binding domain of insulin-like growth factor binding protein (IGFBP)-3 increases susceptibility of IGFBP-3 to proteolysis [J].
Durham, SK ;
Suwanichkul, A ;
Hayes, JD ;
Herington, AC ;
Powell, DR ;
Campbell, PG .
HORMONE AND METABOLIC RESEARCH, 1999, 31 (2-3) :216-225
[6]  
Garcia-Closas Montserrat, 2000, Journal of the National Cancer Institute Monographs, P147
[7]   Circulating concentrations of insulin-like growth factor-I and risk of breast cancer [J].
Hankinson, SE ;
Willett, WC ;
Colditz, GA ;
Hunter, DJ ;
Michaud, DS ;
Deroo, B ;
Rosner, B ;
Speizer, FE ;
Pollak, M .
LANCET, 1998, 351 (9113) :1393-1396
[8]  
Jehle Peter M., 2003, Eur J Intern Med, V14, P32, DOI 10.1016/S0953-6205(02)00183-8
[9]   Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women [J].
Kaaks, R ;
Toniolo, P ;
Akhmedkhanov, A ;
Lukanova, A ;
Biessy, C ;
Dechaud, H ;
Rinaldi, S ;
Zeleniuch-Jacquotte, A ;
Shore, RE ;
Riboli, E .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (19) :1592-1600
[10]   A MONOCLONAL-ANTIBODY TO HUMAN INSULIN-LIKE GROWTH FACTOR-I - CHARACTERIZATION, USE IN RADIOIMMUNOASSAY AND EFFECT ON THE BIOLOGICAL-ACTIVITIES OF THE GROWTH-FACTOR [J].
MORRELL, DJ ;
DADI, H ;
MORE, J ;
TAYLOR, AM ;
DABESTANI, A ;
BUCHANAN, CR ;
HOLDER, AT ;
PREECE, MA .
JOURNAL OF MOLECULAR ENDOCRINOLOGY, 1989, 2 (03) :201-206